MCID: MSC012
MIFTS: 36

Muscular Dystrophy, Duchenne and Becker Type

Categories: Muscle diseases

Aliases & Classifications for Muscular Dystrophy, Duchenne and Becker Type

MalaCards integrated aliases for Muscular Dystrophy, Duchenne and Becker Type:

Name: Muscular Dystrophy, Duchenne and Becker Type 76
Duchenne and Becker Muscular Dystrophy 25 73
Muscular Dystrophy, Duchenne and Becker Types 25
Dystrophy, Muscular, Becker/duchenne Type 40
Muscular Dystrophy, Pseudohypertrophic 25
Duchenne/becker Muscular Dystrophy 25
Dbmd 25

Classifications:



Summaries for Muscular Dystrophy, Duchenne and Becker Type

Genetics Home Reference : 25 Muscular dystrophies are a group of genetic conditions characterized by progressive muscle weakness and wasting (atrophy). The Duchenne and Becker types of muscular dystrophy are two related conditions that primarily affect skeletal muscles, which are used for movement, and heart (cardiac) muscle. These forms of muscular dystrophy occur almost exclusively in males.

MalaCards based summary : Muscular Dystrophy, Duchenne and Becker Type, also known as duchenne and becker muscular dystrophy, is related to muscular dystrophy, pseudohypertrophic, with internalized capillaries and fukuyama type muscular dystrophy. The drugs Ramipril and Carvedilol have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, heart and bone, and related phenotypes are intellectual disability, mild and gait disturbance

Wikipedia : 76 Muscular dystrophy (MD) is a group of muscle diseases that results in increasing weakening and breakdown... more...

Related Diseases for Muscular Dystrophy, Duchenne and Becker Type

Diseases related to Muscular Dystrophy, Duchenne and Becker Type via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 17)
# Related Disease Score Top Affiliating Genes
1 muscular dystrophy, pseudohypertrophic, with internalized capillaries 12.2
2 fukuyama type muscular dystrophy 11.3
3 muscular dystrophy, becker type 11.2
4 muscular dystrophy 11.2
5 muscular dystrophy, duchenne type 10.2
6 aging 10.2
7 glycerol kinase deficiency 10.1
8 dilated cardiomyopathy 10.1
9 liver disease 10.1
10 spinal muscular atrophy 10.1
11 nonalcoholic fatty liver disease 10.1
12 epilepsy 10.1
13 ischemia 10.1
14 muscular atrophy 10.1
15 fatty liver disease 10.1
16 myotonic dystrophy 10.1
17 myotonia atrophica 10.1

Graphical network of the top 20 diseases related to Muscular Dystrophy, Duchenne and Becker Type:



Diseases related to Muscular Dystrophy, Duchenne and Becker Type

Symptoms & Phenotypes for Muscular Dystrophy, Duchenne and Becker Type

Human phenotypes related to Muscular Dystrophy, Duchenne and Becker Type:

32 (show all 13)
# Description HPO Frequency HPO Source Accession
1 intellectual disability, mild 32 occasional (7.5%) HP:0001256
2 gait disturbance 32 hallmark (90%) HP:0001288
3 joint stiffness 32 frequent (33%) HP:0001387
4 hypertrophic cardiomyopathy 32 frequent (33%) HP:0001639
5 developmental regression 32 occasional (7.5%) HP:0002376
6 scoliosis 32 frequent (33%) HP:0002650
7 slender long bone 32 frequent (33%) HP:0003100
8 myopathy 32 hallmark (90%) HP:0003198
9 skeletal muscle atrophy 32 hallmark (90%) HP:0003202
10 elevated serum creatine phosphokinase 32 hallmark (90%) HP:0003236
11 hyperlordosis 32 frequent (33%) HP:0003307
12 emg abnormality 32 hallmark (90%) HP:0003457
13 reduced bone mineral density 32 frequent (33%) HP:0004349

Drugs & Therapeutics for Muscular Dystrophy, Duchenne and Becker Type

Drugs for Muscular Dystrophy, Duchenne and Becker Type (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ramipril Approved Phase 4 87333-19-5 5362129
2
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
3
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 171596-29-5 110635
4
protease inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
5 Adrenergic Agents Phase 4,Phase 3,Not Applicable
6 Adrenergic alpha-1 Receptor Antagonists Phase 4
7 Adrenergic alpha-Antagonists Phase 4
8 Adrenergic Antagonists Phase 4
9 Adrenergic beta-Antagonists Phase 4
10 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
12 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
13 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1
15 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Antibiotics, Antitubercular Phase 4
19 Deflazacort Approved, Investigational Phase 3,Phase 1,Phase 2 14484-47-0
20
Prednisone Approved, Vet_approved Phase 3,Phase 1,Phase 2 53-03-2 5865
21
Spironolactone Approved Phase 3,Not Applicable 1952-01-7, 52-01-7 5833
22
Metformin Approved Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
23
Eplerenone Approved Phase 3,Not Applicable 107724-20-9 150310 443872
24
Enalaprilat Approved Phase 3 76420-72-9 6917719
25
Zoledronic acid Approved Phase 3 118072-93-8 68740
26
Enalapril Approved, Vet_approved Phase 3 75847-73-3 5362032 40466924
27
Lisinopril Approved, Investigational Phase 2, Phase 3,Not Applicable 83915-83-7, 76547-98-3 5362119
28
Idebenone Approved, Investigational Phase 3,Phase 2 58186-27-9
29
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
30
Tamoxifen Approved Phase 3,Phase 1 10540-29-1 2733526
31
Nebivolol Approved, Investigational Phase 3 152520-56-4, 99200-09-6, 118457-14-0 71301
32 tannic acid Approved, Nutraceutical Phase 3
33
Creatine Approved, Investigational, Nutraceutical Phase 2, Phase 3,Phase 3,Not Applicable 57-00-1 586
34
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 2, Phase 3,Phase 3 303-98-0 5281915
35
Epigallocatechin gallate Investigational Phase 2, Phase 3 989-51-5 65064
36 diuretics Phase 3,Phase 1,Not Applicable
37 Natriuretic Agents Phase 3,Phase 1,Not Applicable
38 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 glucocorticoids Phase 3,Phase 2,Phase 1
40 Immunosuppressive Agents Phase 3,Phase 1
41 Ubiquinone Phase 3,Phase 2
42 Micronutrients Phase 3,Phase 2,Not Applicable
43 Adrenergic Agonists Phase 3,Not Applicable
44 Mineralocorticoid Receptor Antagonists Phase 3,Not Applicable
45 Mineralocorticoids Phase 3,Not Applicable
46 Neuroprotective Agents Phase 2, Phase 3
47 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
48 Trace Elements Phase 3,Phase 2,Not Applicable
49 Diphosphonates Phase 3
50 Hormones Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 234)
# Name Status NCT ID Phase Drugs
1 The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy Unknown status NCT00606775 Phase 4 Carvedilol
2 Ramipril Versus Carvedilol in Duchenne and Becker Patients Unknown status NCT00819845 Phase 4 carvedilol;ramipril
3 Tadalafil in Becker Muscular Dystrophy Completed NCT01070511 Phase 4 Tadalafil;Placebo
4 Stacking Exercises Aid the Decline in FVC and Sick Time Active, not recruiting NCT01999075 Phase 4
5 Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy Unknown status NCT02147639 Phase 2, Phase 3
6 L-citrulline and Metformin in Duchenne's Muscular Dystrophy Completed NCT01995032 Phase 3 750 mg metformin and 7.5 g L-citrulline daily p.o.;Placebo
7 High-dose Prednisone in Duchenne Muscular Dystrophy Completed NCT00110669 Phase 3 Prednisone
8 Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial Completed NCT02432885 Phase 3 Enalapril
9 Phase III Randomized, Double-Blind Study of Prednisone for Duchenne Muscular Dystrophy Completed NCT00004646 Phase 3 prednisone
10 A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy Completed NCT01254019 Phase 3 GSK2402968 6mg/kg/week
11 Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD) Completed NCT01027884 Phase 3 Placebo;Idebenone
12 Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy Completed NCT01826487 Phase 3 Ataluren;Placebo
13 Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy Completed NCT00016653 Phase 2, Phase 3 Creatine Monohydrate;Glutamine
14 A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD) Completed NCT00018109 Phase 3 glutamine;creatine monohydrate
15 Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies Completed NCT01126697 Phase 2, Phase 3 Coenzyme Q10 and Lisinopril
16 An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions Completed NCT00799266 Phase 3 Zoledronic acid;Placebo;Zoledronic acid;Placebo
17 Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy Recruiting NCT03039686 Phase 2, Phase 3 RO7239361;Placebo for RO7239361
18 Tamoxifen in Duchenne Muscular Dystrophy Recruiting NCT03354039 Phase 3 Tamoxifen;Matching placebo
19 Study of SRP-4045 and SRP-4053 in DMD Patients Recruiting NCT02500381 Phase 3 SRP-4045;SRP-4053;Placebo
20 Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy Recruiting NCT02851797 Phase 3 givinostat;placebo
21 A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids Recruiting NCT02814019 Phase 3 Idebenone 150 mg film-coated tablets;placebo
22 Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study Recruiting NCT03373968 Phase 2, Phase 3 Givinostat
23 Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy Recruiting NCT03179631 Phase 3 Ataluren;PLACEBO
24 1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids Recruiting NCT01197300 Phase 3 zoledronic acid
25 Study of Eteplirsen in DMD Patients Active, not recruiting NCT02255552 Phase 3 eteplirsen
26 Finding the Optimum Regimen for Duchenne Muscular Dystrophy Active, not recruiting NCT01603407 Phase 3 Prednisone;Prednisone;Deflazacort
27 Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy Active, not recruiting NCT02354352 Phase 3 Eplerenone;Spironolactone
28 Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy Active, not recruiting NCT01183767 Phase 2, Phase 3 Epigallocatechin-Gallate;Placebo
29 Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy Active, not recruiting NCT01648634 Phase 3 Nebivolol;Placebo
30 Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and Canada Active, not recruiting NCT01557400 Phase 3 Ataluren
31 Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy Active, not recruiting NCT02090959 Phase 3 Ataluren
32 Study of Ataluren for Previously Treated Patients With nmDBMD in the US Enrolling by invitation NCT01247207 Phase 3 Ataluren
33 An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy Not yet recruiting NCT03532542 Phase 3 Casimersen;Golodirsen
34 Phase 2b Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD) Terminated NCT00847379 Phase 2, Phase 3 Ataluren (PTC124)
35 A Study of Tadalafil for Duchenne Muscular Dystrophy Terminated NCT01865084 Phase 3 Tadalafil;Placebo
36 Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy Terminated NCT01480245 Phase 3 GSK2402968
37 CoQ10 and Prednisone in Non-Ambulatory DMD Terminated NCT00308113 Phase 3 Prednisone
38 A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects Terminated NCT01803412 Phase 3 Drisapersen;Drisapersen;Drisapersen
39 Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders Terminated NCT00839033 Phase 3
40 Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol Withdrawn NCT01890798 Phase 3 Drisapersen
41 Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular Dystrophy Unknown status NCT02285673 Phase 1, Phase 2
42 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy Unknown status NCT01610440 Phase 1, Phase 2
43 Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy Unknown status NCT01207908 Phase 1, Phase 2 IGF-1
44 Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy Unknown status NCT01834040 Phase 1, Phase 2
45 Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy Unknown status NCT01918384 Phase 2 NPC-14;Placebo
46 Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Muscular Dystrophy. Unknown status NCT01834066 Phase 1, Phase 2
47 Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy Completed NCT00264888 Phase 2 PTC124
48 Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients Completed NCT01396239 Phase 2 AVI-4658 (Eteplirsen)
49 A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) Completed NCT02760264 Phase 2 Vamorolone 0.25 mg/kg/day;Vamorolone 0.75 mg/kg/day;Vamorolone 2.0 mg/kg/day;Vamorolone 6.0 mg/kg/day
50 An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) Completed NCT02760277 Phase 2 Vamorolone 0.25 mg/day/day;Vamorolone 0.75 mg/day/day;Vamorolone 2.0 mg/day/day;Vamorolone 6.0 mg/day/day

Search NIH Clinical Center for Muscular Dystrophy, Duchenne and Becker Type

Genetic Tests for Muscular Dystrophy, Duchenne and Becker Type

Anatomical Context for Muscular Dystrophy, Duchenne and Becker Type

MalaCards organs/tissues related to Muscular Dystrophy, Duchenne and Becker Type:

41
Skeletal Muscle, Heart, Bone, Testes, Brain, Liver

Publications for Muscular Dystrophy, Duchenne and Becker Type

Articles related to Muscular Dystrophy, Duchenne and Becker Type:

(show top 50) (show all 164)
# Title Authors Year
1
Skeletal Muscle Metabolism in Duchenne and Becker Muscular Dystrophy-Implications for Therapies. ( 29925809 )
2018
2
Myocardial Fibrosis in Duchenne and Becker Muscular Dystrophy. ( 28492916 )
2017
3
Genetic analysis of the dystrophin gene in children with Duchenne and Becker muscular dystrophies. ( 27750387 )
2017
4
Myocardial Fibrosis in Duchenne and Becker Muscular Dystrophy-Reply. ( 28492933 )
2017
5
The PJ Nicholoff Steroid Protocol for Duchenne and Becker Muscular Dystrophy and Adrenal Suppression. ( 28744411 )
2017
6
Evaluation of point mutations in dystrophin gene in Iranian Duchenne and Becker muscular dystrophy patients: introducing three novel variants. ( 27350676 )
2016
7
Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies. ( 26974331 )
2016
8
Age at onset of first signs or symptoms predicts age at loss of ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet. ( 26966795 )
2016
9
Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial. ( 27926769 )
2016
10
Pain in adolescents with spinal muscular atrophy and Duchenne and Becker muscular dystrophy. ( 25978940 )
2015
11
Cardiac involvement in female Duchenne and Becker muscular dystrophy carriers in comparison to their first-degree male relatives: a comparative cardiovascular magnetic resonance study. ( 26113120 )
2015
12
Analysis of dystrophin gene in Iranian Duchenne and Becker muscular dystrophies patients and identification of a novel mutation. ( 26081009 )
2015
13
Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies. ( 26295289 )
2015
14
Dystrophin genotype-cardiac phenotype correlations in Duchenne and Becker muscular dystrophies using cardiac magnetic resonance imaging. ( 25702278 )
2015
15
A comprehensive database of Duchenne and Becker muscular dystrophy patients (0-18 years old) in East China. ( 25612904 )
2015
16
Cardiac involvement in Duchenne and Becker muscular dystrophy. ( 26225202 )
2015
17
Genetics and emerging treatments for Duchenne and Becker muscular dystrophy. ( 26022172 )
2015
18
Dystrophin hydrophobic regions in the pathogenesis of Duchenne and Becker muscular dystrophies. ( 26042512 )
2015
19
A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. ( 24780148 )
2014
20
Duchenne and Becker muscular dystrophies. ( 25037084 )
2014
21
Correlates of care for young men with duchenne and becker muscular dystrophy. ( 23558904 )
2014
22
Whole dystrophin gene analysis by next-generation sequencing: a comprehensive genetic diagnosis of Duchenne and Becker muscular dystrophy. ( 24770780 )
2014
23
Genetic diagnosis of Duchenne and Becker muscular dystrophy using multiplex ligation-dependent probe amplification in Rwandan patients. ( 24213305 )
2013
24
Functional muscle ischemia in Duchenne and Becker muscular dystrophy. ( 24391598 )
2013
25
Differences in carrier frequency between mothers of Duchenne and Becker muscular dystrophy patients. ( 24225992 )
2013
26
Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy). ( 23601510 )
2013
27
CMR detects subclinical cardiomyopathy in mother-carriers of Duchenne and Becker muscular dystrophy. ( 23579015 )
2013
28
Parental perspectives on the diagnostic process for Duchenne and Becker muscular dystrophy. ( 23494880 )
2013
29
[Recommendations of good practices for the genetic diagnosis of Duchenne and Becker muscular dystrophies]. ( 22538063 )
2012
30
Genetic diagnosis of Duchenne and Becker muscular dystrophy using next-generation sequencing technology: comprehensive mutational search in a single platform. ( 21969337 )
2011
31
Quality assurance for Duchenne and Becker muscular dystrophy genetic testing: development of a genomic DNA reference material panel. ( 21354051 )
2011
32
Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy. ( 21700587 )
2011
33
Duchenne and Becker muscular dystrophy presenting as nonalcoholic fatty liver disease. ( 21970998 )
2011
34
Disparities in the diagnostic process of Duchenne and Becker muscular dystrophy. ( 21836521 )
2011
35
Serum transaminase levels in boys with Duchenne and Becker muscular dystrophy. ( 21149430 )
2011
36
Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy. ( 20207610 )
2010
37
Cardiac assessment in duchenne and becker muscular dystrophies. ( 20857240 )
2010
38
Quantitative ultrasound using backscatter analysis in Duchenne and Becker muscular dystrophy. ( 20817454 )
2010
39
Respiratory surveillance of patients with Duchenne and Becker muscular dystrophy. ( 21791803 )
2009
40
Adherence to american academy of pediatrics recommendations for cardiac care among female carriers of duchenne and becker muscular dystrophy. ( 19254982 )
2009
41
Recurrence risk due to germ line mosaicism: Duchenne and Becker muscular dystrophy. ( 19475718 )
2009
42
Duchenne and Becker muscular dystrophy: contribution of a molecular and immunohistochemical analysis in diagnosis in Morocco. ( 19461958 )
2009
43
Current understanding and management of dilated cardiomyopathy in Duchenne and Becker muscular dystrophy. ( 19432907 )
2009
44
Life expectancy and death from cardiomyopathy amongst carriers of Duchenne and Becker muscular dystrophy in Scotland. ( 17932095 )
2008
45
Electromyographic pattern in Duchenne and Becker muscular dystrophy. Part II. Electromyographic pattern in Becker muscular dystrophy in comparison with Duchenne muscular dystrophy. ( 18837193 )
2008
46
Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy. ( 18228186 )
2008
47
Electromyographic pattern in Duchenne and Becker muscular dystrophy. Part I: Electromyographic pattern in subsequent stages of muscle lesion in Duchenne muscular dystrophy. ( 18837192 )
2008
48
Body composition and resting energy expenditure of individuals with Duchenne and Becker muscular dystrophy. ( 19063812 )
2008
49
Duchenne and Becker muscular dystrophy: a molecular and immunohistochemical approach. ( 17420831 )
2007
50
Measurement of the clinical utility of a combined mutation detection protocol in carriers of Duchenne and Becker muscular dystrophy. ( 17259292 )
2007

Variations for Muscular Dystrophy, Duchenne and Becker Type

Copy number variations for Muscular Dystrophy, Duchenne and Becker Type from CNVD:

7 (show all 41)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 262120 X 31046000 31495434 Deletion Duchenne and Becker muscular dystrophies
2 262121 X 31046000 31499751 Deletion Duchenne and Becker muscular dystrophies
3 262151 X 31503750 31715250 Duplication Duchenne and Becker muscular dystrophies
4 262152 X 31518523 31948537 Deletion Duchenne and Becker muscular dystrophies
5 262154 X 31533250 31645750 Deletion Duchenne and Becker muscular dystrophies
6 262156 X 31555638 31864405 Deletion Duchenne and Becker muscular dystrophies
7 262157 X 31563750 31981750 Deletion Duchenne and Becker muscular dystrophies
8 262158 X 31573250 31702250 Deletion Duchenne and Becker muscular dystrophies
9 262159 X 31578750 31989750 Deletion Duchenne and Becker muscular dystrophies
10 262160 X 31584297 31995179 Deletion Duchenne and Becker muscular dystrophies
11 262162 X 31607250 31615750 Deletion Duchenne and Becker muscular dystrophies
12 262163 X 31608059 31811249 Deletion Duchenne and Becker muscular dystrophies
13 262164 X 31620852 31877576 Deletion Duchenne and Becker muscular dystrophies
14 262165 X 31637403 31824256 Deletion Duchenne and Becker muscular dystrophies
15 262166 X 31641000 31661000 Deletion Duchenne and Becker muscular dystrophies
16 262168 X 31703750 31969750 Deletion Duchenne and Becker muscular dystrophies
17 262169 X 31720250 32212750 Duplication Duchenne and Becker muscular dystrophies
18 262170 X 31723560 31799723 Deletion Duchenne and Becker muscular dystrophies
19 262171 X 31736096 31781840 Deletion Duchenne and Becker muscular dystrophies
20 262172 X 31736250 31784750 Deletion Duchenne and Becker muscular dystrophies
21 262192 X 31797750 31939750 Deletion Duchenne and Becker muscular dystrophies
22 262193 X 31838750 32014750 Deletion Duchenne and Becker muscular dystrophies
23 262194 X 31855778 32003438 Deletion Duchenne and Becker muscular dystrophies
24 262195 X 31867000 32037000 Deletion Duchenne and Becker muscular dystrophies
25 262216 X 32030750 32191750 Duplication Duchenne and Becker muscular dystrophies
26 262218 X 32073457 32469353 Deletion Duchenne and Becker muscular dystrophies
27 262219 X 32094750 32474250 Deletion Duchenne and Becker muscular dystrophies
28 262221 X 32098595 32181888 Deletion Duchenne and Becker muscular dystrophies
29 262252 X 32275827 32453261 Duplication Duchenne and Becker muscular dystrophies
30 262255 X 32313750 32622750 Deletion Duchenne and Becker muscular dystrophies
31 262265 X 32425250 32488250 Deletion Duchenne and Becker muscular dystrophies
32 262267 X 32444250 32455250 Deletion Duchenne and Becker muscular dystrophies
33 262279 X 32521250 32633250 Deletion Duchenne and Becker muscular dystrophies
34 262281 X 32561500 32628500 Duplication Duchenne and Becker muscular dystrophies
35 262282 X 32572850 32629450 Duplication Duchenne and Becker muscular dystrophies
36 262283 X 32575950 32719450 Deletion Duchenne and Becker muscular dystrophies
37 262284 X 32662600 32842800 Deletion Duchenne and Becker muscular dystrophies
38 262285 X 32676750 32794750 Duplication Duchenne and Becker muscular dystrophies
39 262288 X 32706289 32779413 Deletion Duchenne and Becker muscular dystrophies
40 262291 X 32761242 33013846 Duplication Duchenne and Becker muscular dystrophies
41 262292 X 32761250 33026750 Duplication Duchenne and Becker muscular dystrophies

Expression for Muscular Dystrophy, Duchenne and Becker Type

Search GEO for disease gene expression data for Muscular Dystrophy, Duchenne and Becker Type.

Pathways for Muscular Dystrophy, Duchenne and Becker Type

GO Terms for Muscular Dystrophy, Duchenne and Becker Type

Sources for Muscular Dystrophy, Duchenne and Becker Type

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....